CLAIMS

1. A compound of the formula:



(I)

wherein:

X is selected from the group consisting of trihalomethyl, C_1-C_6 alkyl, and a group of formula II:



(II)

wherein:

R_3 and R_4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C_1-C_6 alkyl; C_1-C_6 alkoxy; carboxy; C_1-C_6 trihaloalkyl; and cyano;

Z is selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein Z is selected from the group consisting of substituted and unsubstituted heteroaryl; or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 2 wherein Z is selected from the group consisting of substituted and unsubstituted indolyl, furyl, thienyl, pyridyl, benzofuryl, benzothienyl, imidazolyl, pyrazolyl, thiazolyl, benzothazolyl, quinolinyl, and 4-(2-benzyloxazolyl); or a pharmaceutically

acceptable salt thereof.

4. A compound according to claim 1 wherein Z is 3-indolyl; or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 1 wherein X is trifluoromethyl.

6. A compound according to claim 1 wherein X is a group according to formula II wherein R_3 and R_4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C_1-C_6 alkyl; C_1-C_6 alkoxy; carboxy; C_1-C_6 trihaloalkyl; and cyano; or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 6 wherein R_3 and R_4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C_1-C_6 alkyl; C_1-C_6 alkoxy; and carboxy; or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 7 wherein Z is selected from the group consisting of unsubstituted phenyl; and mono-, di- and tri-substituted phenyl.

9. A compound according to claim 8 wherein Z is phenyl substituted with one or more of halogen, hydroxyl, nitro, C_1-C_6 alkyl, C_1-C_6 alkoxy, or carboxy; or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 9 wherein Z is the group



wherein R_1 and R_2 are independently selected from the group consisting of

hydrogen, fluorine, bromine, chlorine, C_1-C_3 alkyl, C_1-C_3 alkoxy, hydroxyl and nitro; or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 7 wherein Z is substituted or unsubstituted indolyl, furyl, thienyl, pyridyl or benzofuryl; or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 11 wherein 11 is 3-indolyl; or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1 which is 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-phenyl-2-pyrazoline; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 which is 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline; or a pharmaceutically acceptable salt thereof.

15. A compound of the formula V:



(V)

wherein:

X is selected from the group consisting of trihalomethyl, C_1-C_6 alkyl, and a group of formula II:


(II)

wherein:

R_3 and R_4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C_1-C_6 alkyl; C_1-C_6 alkoxy; carboxy; C_1-C_6 trihaloalkyl; and cyano;

Z is substituted or unsubstituted heteroaryl; and

R_5 is selected from the group consisting of

wherein R_6 is C_1-C_6 alkyl and M is Na, K or Li; or a pharmaceutically acceptable salt thereof.

16. A compound of the formula V:


(V)

wherein:

X is a group of formula II:


(II)

wherein:

R_3 and R_4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C_1-C_6 alkyl; C_1-C_6 alkoxy; carboxy; C_1-C_6 trihaloalkyl; and cyano;

Z is selected from the group consisting of substituted and unsubstituted aryl; and

R_5 is selected from the group consisting of

wherein R_6 is C_1-C_6 alkyl and M is Na, K or Li; or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

18. A method for treating a cyclooxygenase-mediated disorder comprising administering to a patient in need of such treatment an effective amount of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

19. A method for treating inflammation or an inflamation-mediated disorder comprising administering to a subject in need of such treatment an effective amount of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

20. A method for treating a neoplasia comprising administering to a subject in need of such treatment an effective amount of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable



(IV)

wherein X and Z are so defined;

with 4-sulfamyl phenyl hydrazine or salt thereof; and

(b) isolating a compound according to formula I from the reaction products.

23. A method according to claim 22 wherein Z is substituted or unsubstituted heteroaryl.

24. A method according to claim 22 wherein X is a radical of formula II.

25. A method according to claim 22 wherein the group X in the reactant compound of formula II is selected from the group consisting of trifluoromethyl, C_1-C_6 alkyl, and a radical of formula II:



(II)

wherein:

wherein R_3 and R_4 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, C_1-C_6 alkyl, C_1-C_6 alkoxy; and carboxy.

26. An isolated optical isomer of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

salt thereof.

21. A method for treating an angiogenesis-mediated disorder administering to a subject in need of such treatment an effective amount of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

22. A method for producing a compound of formula I



(I)

wherein:

the group X is selected from the group consisting of trihalomethyl, C_1-C_6 alkyl, and a radical of formula II:



(II)

wherein:

wherein R_3 and R_4 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, C_1-C_6 alkyl, C_1-C_6 alkoxy; carboxy; C_1-C_6 trihaloalkyl; and cyano; and

Z is selected from the group consisting of substituted and unsubstituted aryl;

the method comprising:

(a) reacting a compound of the formula IV